Search Results - "ROCCA, Andrea"

Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy by Hong, Sung Pil, Chan, Thalia E., Lombardo, Ylenia, Corleone, Giacomo, Rotmensz, Nicole, Bravaccini, Sara, Rocca, Andrea, Pruneri, Giancarlo, McEwen, Kirsten R., Coombes, R. Charles, Barozzi, Iros, Magnani, Luca

“…Resistant tumours are thought to arise from the action of Darwinian selection on genetically heterogenous cancer cell populations. However, simple clonal…”
Get full text

Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer by Rocca, Andrea, Farolfi, Alberto, Bravaccini, Sara, Schirone, Alessio, Amadori, Dino

“…The cyclin D-cyclin-dependent kinases 4 and 6 (CDK4/6)-retinoblastoma (Rb) pathway, governing the cell cycle restriction point, is frequently altered in breast…”
Get more information

Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer by DELLAPASQUA, Silvia, BERTOLINI, Francesco, PIETRI, Elisabetta, COLLEONI, Marco, BAGNARDI, Vincenzo, CAMPAGNOLI, Elisabetta, SCARANO, Eloise, TORRISI, Rosalba, SHAKED, Yuval, MANCUSO, Patrizia, GOLDHIRSCH, Aron, ROCCA, Andrea

“…Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. When used in association with targeted antiangiogenic drugs, it was more…”
Get full text

Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines  for the adjuvant treatment of early breast cancer? by Bravaccini, Sara, Rocca, Andrea, Bronte, Giuseppe

Get full text

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors by Farolfi, Alberto, Melegari, Elisabetta, Aquilina, Michele, Scarpi, Emanuela, Ibrahim, Toni, Maltoni, Roberta, Sarti, Samanta, Cecconetto, Lorenzo, Pietri, Elisabetta, Ferrario, Cristiano, Fedeli, Anna, Faedi, Marina, Nanni, Oriana, Frassineti, Giovanni Luca, Amadori, Dino, Rocca, Andrea

“…Although adjuvant trastuzumab improves survival in patients with HER2-positive early breast cancer, there is growing concern about the long-term effect of…”
Get more information

Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab by Palleschi, Michela, Prochowski Iamurri, Andrea, Scarpi, Emanuela, Mariotti, Marita, Maltoni, Roberta, Mannozzi, Francesca, Barone, Domenico, Paganelli, Giovanni, Casi, Michela, Giampalma, Emanuela, De Giorgi, Ugo, Rocca, Andrea

“…Body composition parameters (BCp) have been associated with outcome in different tumor types. However, their prognostic value in patients with HER2-positive…”
Get full text

Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer by Rossi, Tania, Gallerani, Giulia, Angeli, Davide, Cocchi, Claudia, Bandini, Erika, Fici, Pietro, Gaudio, Michele, Martinelli, Giovanni, Rocca, Andrea, Maltoni, Roberta, Fabbri, Francesco

“…Circulating tumor cells (CTCs) are a rare population of cells representing a key player in the metastatic cascade. They are recognized as a validated tool for…”
Get full text

Complement protein C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma by Balduit, Andrea, Vidergar, Romana, Zacchi, Paola, Mangogna, Alessandro, Agostinis, Chiara, Grandolfo, Micaela, Bottin, Cristina, Salton, Francesco, Confalonieri, Paola, Rocca, Andrea, Zanconati, Fabrizio, Confalonieri, Marco, Kishore, Uday, Ghebrehiwet, Berhane, Bulla, Roberta

“…Complement component C1q can act as a pro-tumorigenic factor in the tumor microenvironment (TME). The TME in malignant pleural mesothelioma (MPM) is rich in…”
Get full text

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? by Bronte, Giuseppe, Rocca, Andrea, Ravaioli, Sara, Puccetti, Maurizio, Tumedei, Maria Maddalena, Scarpi, Emanuela, Andreis, Daniele, Maltoni, Roberta, Sarti, Samanta, Cecconetto, Lorenzo, Fedeli, Anna, Pietri, Elisabetta, De Simone, Valeria, Asioli, Silvia, Amadori, Dino, Bravaccini, Sara

“…Androgen receptor (AR) is widely expressed in breast cancer (BC) but its role in estrogen receptor (ER)-positive tumors is still controversial. The AR/ER ratio…”
Get full text

Indigenous hepatitis E virus genotype 1 infection, Uruguay by Mirazo, Santiago, Mainardi, Victoria, Ramos, Natalia, Gerona, Solange, Rocca, Andrea, Arbiza, Juan

Get full text

Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ by Farolfi, Alberto, Petracci, Elisabetta, Serra, Luigi, Ravaioli, Alessandra, Bravaccini, Sara, Ravaioli, Sara, Tumedei, Maria Maddalena, Ulivi, Paola, Canale, Matteo, Puccetti, Maurizio, Falcini, Fabio, Folli, Secondo, Curcio, Annalisa, Rocca, Andrea

“…Women with a diagnosis of ductal carcinoma in situ (DCIS) have a high risk of developing a second breast event (SBE). The immune system might play a role in…”
Get full text

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer by Maltoni, Roberta, Palleschi, Michela, Ravaioli, Sara, Tumedei, Maria Maddalena, Rocca, Andrea, Melegari, Elisabetta, Altini, Mattia, Puccetti, Maurizio, Manunta, Silvia, Bravaccini, Sara

“…Keup and colleagues provide liquid biopsy preliminary results by sequencing variants in circulating tumor cells (CTCs) and cell-free deoxyribonucleic acid…”
Get full text

Progress with palbociclib in breast cancer: latest evidence and clinical considerations by Rocca, Andrea, Schirone, Alessio, Maltoni, Roberta, Bravaccini, Sara, Cecconetto, Lorenzo, Farolfi, Alberto, Bronte, Giuseppe, Andreis, Daniele

“…Deregulation of the cell cycle is a hallmark of cancer, and research on cell cycle control has allowed identification of potential targets for anticancer…”
Get full text

Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients by Generali, Daniele, Rocca, Andrea, Strina, Carla, Milani, Manuela, Fiorino, Enrico, Cervoni, Valeria, Azzini, Carlo, Saracino, Antonella, Ciliberto, Ingnazio, Ziglioli, Nicoletta, Alberio, Marzia, Giudici, Fabiola, Dester, Martina, Ciani, Oriana, Fornaro, Giulia, Aguggini, Sergio, Dreezen, Christa, Pronin, Darina, Ende, Stefanie

“…The aim of this study was to assess the prognostic performance of the 70-gene signature, MammaPrint, in an Italian single-center prospective cohort of…”
Get full text

Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? by Bronte, Giuseppe, Bravaccini, Sara, Ravaioli, Sara, Puccetti, Maurizio, Scarpi, Emanuela, Andreis, Daniele, Tumedei, Maria Maddalena, Sarti, Samanta, Cecconetto, Lorenzo, Pietri, Elisabetta, De Simone, Valeria, Maltoni, Roberta, Bonafè, Massimiliano, Amadori, Dino, Rocca, Andrea

“…Genomic studies have shown that the androgen receptor (AR) pathway plays an important role in some breast cancer subtypes. However few data are present on the…”
Get full text

Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer by Rocca, Andrea, Cortesi, Pietro, Cortesi, Laura, Gianni, Lorenzo, Matteucci, Federica, Fantini, Lorenzo, Maestri, Antonio, Giunchi, Donata Casadei, Cavanna, Luigi, Ciani, Rosa, Falcini, Fabio, Bagni, Antonella, Meldoli, Elena, Dall’Agata, Monia, Volpi, Roberta, Andreis, Daniele, Nanni, Oriana, Curcio, Annalisa, Lucchi, Leonardo, Amadori, Dino, Fedeli, Anna

“…Background: The aim of this study was to improve activity over single human epidermal growth factor receptor 2 (HER2)-blockade sequential neaodjuvant regimens…”
Get full text

CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study by Rocca, Andrea, Giudici, Fabiola, Donofrio, Carmine Antonio, Bottin, Cristina, Pinamonti, Maurizio, Ferrari, Benvenuto, Schettini, Francesco, Pineda, Estela, Panni, Stefano, Cominetti, Marika, D'Auria, Patrizia, Bianchini, Simonetta, Varotti, Elena, Ungari, Marco, Ciccarelli, Stefano, Filippini, Marzia, Brenna, Sarah, Fiori, Valentina, Di Mambro, Tomas, Sparti, Angelo, Magnani, Mauro, Zanconati, Fabrizio, Generali, Daniele, Fioravanti, Antonio

“…Glioblastoma is the most frequent and aggressive brain tumor in adults. This study aims to evaluate the expression and prognostic impact of CD99, a membrane…”
Get full text

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer by Orlando, Laura, Cardillo, Anna, Ghisini, Raffaella, Rocca, Andrea, Balduzzi, Alessandra, Torrisi, Rosalba, Peruzzotti, Giulia, Goldhirsch, Aron, Pietri, Elisabetta, Colleoni, Marco

“…HER2/neu overexpression is linked to promotion of angiogenesis in breast cancer. We therefore tested the activity of the combination of Trastuzumab with…”
Get full text

Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report by Sobhani, Navid, Bouchè, Victoria, Aldegheri, Giovanni, Rocca, Andrea, D'Angelo, Alberto, Giudici, Fabiola, Bottin, Cristina, Donofrio, Carmine Antonio, Pinamonti, Maurizio, Ferrari, Benvenuto, Panni, Stefano, Cominetti, Marika, Aliaga, Jahard, Ungari, Marco, Fioravanti, Antonio, Zanconati, Fabrizio, Generali, Daniele

“…With the advent of immunotherapies, the field of cancer therapy has been revived with new hope, especially for cancers with dismal prognoses, such as the…”
Get full text

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience by Palleschi, Michela, Maltoni, Roberta, Ravaioli, Sara, Vagheggini, Alessandro, Mannozzi, Francesca, Fanini, Francesca, Pirini, Francesca, Tumedei, Maria, Barzotti, Eleonora, Cecconetto, Lorenzo, Sarti, Samanta, Manunta, Silvia, Possanzini, Paola, Fedeli, Anna, Curcio, Annalisa, Altini, Mattia, De Giorgi, Ugo, Rocca, Andrea, Bravaccini, Sara

“…CDK4/6 inhibitors (CDK4/6i) are recommended in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). Up to now, no…”
Get full text